Compare Cassava Sciences Inc (FLNA) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Western Alliance Bancorporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Western Alliance Bancorporation trades at $76.21 (market cap $8.11B). The key difference: Western Alliance Bancorporation is far larger — about 205.8× Cassava Sciences Inc's market cap, and Western Alliance Bancorporation pays a 2.26% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Western Alliance Bancorporation for 3 Days on average.
| FLNA | WAL | |
|---|---|---|
Market Cap | $39.40M | $8.11B |
Volume | 759,018 | 1,479,953 |
Sector | Health | Financials |
52-Week High | $4.64 | $96.08 |
52-Week Low | $0.68 | $66.70 |
Typical Hold Time | 37 Days | 3 Days |
Enterprise Value | -$43.28M | $9.63B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% on the day, with a bearish technical outlook despite strong fundamentals. The company maintains robust profitability with 25.43% net income margin and 13.43% ROE, supported by recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX digital asset platform and participation in major financial conferences, while institutional investors show mixed positioning.
WAL presents a compelling value opportunity with attractive valuation multiples (P/E 8.39, P/B 1.07) and strong analyst support (79% buy ratings, $84.33 consensus target). However, near-term risks include the recent Q2 2026 EPS miss, bearish technical indicators, and regulatory uncertainty around Fed policy changes affecting bank asset thresholds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
